Krishs Krishnan News Today

Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.

• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of...

FDA Approval, Private Placement Funding Buoy Biotech Firm

05.06.2023 - PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company ...

22.05.2023 - PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced that it has ... Seite 1

Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations...

PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate

PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with...

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) has received an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year […]

Should You Buy or Sell Krystal Biotech Stock? Get The Latest KRYS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.